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The eligibility of reperfusion therapy has been expanded to increase the number of patients. 
However, it remains unclear the reperfusion therapy will be beneficial in stroke patients with various 
comorbidities. We developed a reperfusion comorbidity index for predicting 6‑month mortality 
in patients with acute stroke receiving reperfusion therapy. The 19 comorbidities included in the 
Charlson comorbidity index were adopted and modified. We developed a statistical model and 
it was validated using data from a prospective cohort. Among 1026 patients in the retrospective 
nationwide reperfusion therapy registry, 845 (82.3%) had at least one comorbidity. As the number of 
comorbidities increased, the likelihood of mortality within 6 months also increased (p < 0.001). Six out 
of the 19 comorbidities were included for developing the reperfusion comorbidity index on the basis 
of the odds ratios in the multivariate logistic regression analysis. This index showed good prediction 
of 6‑month mortality in the retrospective cohort (area under the curve [AUC], 0.747; 95% CI, 0.704–
0.790) and in 333 patients in the prospective cohort (AUC, 0.784; 95% CI, 0.709–0.859). Consideration 
of comorbidities might be helpful for the prediction of the 6‑month mortality in patients with acute 
ischemic stroke who receive reperfusion therapy.
The eligibility for reperfusion therapy has been expanded to increase the number of patients who would benefit 
from this  treatment1,2. However, the benefit and risk should be considered in screening candidates for reperfusion 
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therapy. Comorbidities are frequently found in patients with stroke and may be associated with patient outcomes, 
including  mortality3,4. In the recent American Heart Association/American Stroke Association guidelines, some 
recommendations have been made on several individual comorbidities, such as diabetes mellitus, myocardial 
infarction, other cardiac diseases, systemic malignancy, end-stage renal disease, dementia, and sickle cell  disease5. 
However, the levels of evidence are low. In addition, whether reperfusion therapy is beneficial in stroke patients 
with various comorbidities remains unclear.
The Charlson comorbidity index (CCI) is widely used in predicting 1-year mortality in various medical 
conditions and includes 19  comorbidities6. We developed a reperfusion comorbidity index primarily based on 
the comorbidities included in the CCI in patients with acute ischemic stroke receiving reperfusion therapy. We 
investigated its predictive ability for mortality within 6 months after reperfusion therapy.
Results
Study population. A total of 1026 patients were included in the retrospective cohort. Their median age 
was 71 (IQR, 62–76) years, and 589 patients (57.4%) were men. The median NIHSS score was 12.5 (IQR, 7–18) 
(Table  1). Of the 1026 enrolled patients, 845 (82.3%) had at least one comorbidity (median, 2 [IQR, 1–3]) 
(Fig.  1A). The most common comorbidity was atrial fibrillation (in 523 patients [51%]), followed by diabe-
tes mellitus (in 432 patients [42.4%]), anemia (in 270 patients [26.3%]), and previous stroke (in 207 patients 
[20.2%]).
The prospective cohort included a total of 333 patients. Their median age was 71 (IQR, 59–78) years, and 208 
patients (62.5%) were men. The median NIHSS score was 11 (IQR, 5–16). The demographic characteristics were 
similar between the retrospective and prospective cohorts, except for the presence/history of hypercholester-
olemia, myocardial infarction, and metastatic cancer; current smoking status; initial NIHSS score; and treatment 
modalities (Supplemental Table 1).
Association of comorbidity with 3‑month modified Rankin Scale (mRS). Among 1026 patients 
who enrolled in the retrospective cohorts, 3-month mRS was unavailable in 22 patients. Of the 1004 patients, 
univariable and multivariate analyses showed that poor functional outcome at 3 months (mRS ≥ 3) was associ-
ated with age, pre stroke mRS, dementia, and diabetes. When we further included initial NIHSS score, multi-
variable analysis revealed that age, pre stroke mRS, initial NIHSS score, dementia, diabetes, and anemia were 
independent predictors of poor functional outcome at 3 months (Supplemental Tables 3 and 4).
Association of comorbidity with 6‑month mortality. Among the 1026 patients, 141 (13.7%) died 
within 6 months. The median number of days until mortality was 12 (IQR, 3–76.5). The direct causes of mortal-
ity were cerebral infarction in 59 patients (41.8%), infection in 18 (12.8%), life-threatening hemorrhage, includ-
ing intracranial hemorrhage in 17 (12.1%), cancer-related mortality in 10 (7.1%), myocardial infarction in 7 
(0.5%), cardiac or pulmonary disease in 7 (0.5%), gastrointestinal hemorrhage in 1 (0.1%), and unknown in 22 
(15.6%). Ten out of 14 patients (71.4%) with metastatic cancer died within 6 months (Table 1). As the number of 
comorbidities increased, the likelihood of mortality within 6 months also increased (2.8% in the patients without 
comorbidity, 7% in those with one comorbidity, 16% in those with two comorbidities, and 26% in those with 
three or more comorbidities; p < 0.001) (Fig. 1B).
Prognostic model for predicting 6‑month mortality. We developed the prognostic model for predict-
ing 6-month mortality using data from the retrospective cohort. For the graphical computation, we created the 
nomogram. We also developed the smartphone application for fast and easy decision-making in clinical practice 
(Fig. 2). The prognostic model was validated in the retrospective cohort using data from the prospective cohort.
The reperfusion comorbidity index without considering initial stroke severity. The multivariate logistic regression 
analysis showed that age, myocardial infarction, congestive heart failure, ulcer disease, diabetes mellitus, anemia, 
and metastatic cancer were independently associated with 6-month mortality (Table 2). These variables were used 
to construct the model of the reperfusion comorbidity index for predicting 6-month mortality. The predicted 
probability of mortality within 6 months without considering initial stroke severity was calculated using the 
following equation: predicted probability = 1/(1 + exp [− A]), where A = − 5.2999 + 0.0357 × age + 0.6666 × myo-
cardial infarction + 0.6622 × congestive heart failure + 1.0187 × ulcer disease + 1.0201 × diabetes melli-
tus + 0.5568 × anemia + 2.8128 × metastatic cancer.
The predictive ability of the reperfusion comorbidity index for 6-month mortality showed an AUC of 0.747 
(95% CI, 0.704–0.790) In the Hosmer and Lemeshow test, the p value was 0.786, indicating that the model was 
suitable (Fig. 3A). The calibration plots showed a close approximation to the logistic calibration of the nomogram. 
ROC comparison for death within 6 months showed that the AUC did not differ between reperfusion comorbid-
ity index (age + 6 comorbidities [myocardial infarction, congestive heart failure, ulcer disease, diabetes mellitus, 
anemia, and metastatic cancer]) and the original CCI (age + 16 comorbidities) (0.747 [95% CI, 0.704–0.790] vs. 
0.758 [95% CI, 0.716–0.800]; p = 0.112) (Fig. 4A). The AUC did not differ between the patients with and without 
successful recanalization (with recanalization, 0.772 [95% CI, 0.717–0.826] vs. without recanalization, 0.729 
[95% CI, 0.634–0.824]; p = 0.439) (Fig. 4B).
In the prospective cohort, the predictive ability of the reperfusion comorbidity without considering initial 
stroke severity showed an AUC of 0.784 (95% CI, 0.709–0.859). In the Hosmer and Lemeshow test, the p value 
was 0.140, indicating that the model was suitable (Fig. 3B).
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The reperfusion comorbidity index considering initial stroke severity. The multivariate logistic regression analy-
sis showed that age, initial NIHSS score, ulcer disease, diabetes mellitus, anemia, and metastatic cancer were 
independently associated with 6-month mortality (Supplemental Table 5). The predicted probability of mortal-
ity within 6 months with considering initial stroke severity was calculated using the following equation: pre-
dicted probability = 1/(1 + exp  [− A]), where A = − 6.2807 + 0.0307 × age + 0.1019 × NIHSS score + 0.8817 × ulcer 
disease + 0.571 × anemia + 0.9953 × diabetes mellitus + 2.4194 × metastatic cancer. ROC comparison for death 
within 6 months showed that the AUC did not differ between the reperfusion comorbidity index considering ini-
tial stroke severity (age, NIHSS score + 4 comorbidities [ulcer disease, diabetes mellitus, anemia, and metastatic 
cancer]) and the original CCI (age, NIHSS score + 16 comorbidities) (0.781 [95% CI, 0.738–0.824] vs. 0.792 [95% 
CI, 0.751–0.832]; p = 0.120) (Supplemental Fig. 1A).
Table 1.  Factors associated with mortality within 6 months. mRS, modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale score; IV tPA, intravenous tissue-type plasminogen activator; IA UK, 
intraarterial urokinase; EVT, endovascular treatment; AIDS, Acquired Immune Deficiency Syndrome.
Death within 6 month (+) Death within 6 month (−) Total
p(N = 141) (N = 885) (N = 1026)
Age 75.0 [69.0;80.0] 70.0 [62.0;76.0] 71.0 [62.0;76.0] < 0.001
Sex 0.415
 Men 76 (53.9) 513 (58.0) 589 (57.4)
 Women 65 (46.1) 372 (42.0) 437 (42.6)
Hypertension 100 (70.9) 632 (71.4) 732 (71.3) 0.985
Hypercholesterolemia 49 (34.8) 272 (30.7) 321 (31.3) 0.391
Current smoking 19 (13.5) 210 (23.7) 229 (22.3) 0.009
Coronary artery disease 36 (25.5) 151 (17.1) 187 (18.2) 0.021
Valvular heart disease 6 (4.3) 34 (3.8) 40 (3.9) 0.999
Pre stroke mRS 0.001
 0 107 (75.9) 791 (89.4) 898 (87.5)
 1 15 (10.6) 38 (4.3) 53 (5.2)
 2 7 (5.0) 20 (2.3) 27 (2.6)
 3 7 (5.0) 22 (2.5) 29 (2.8)
 4 4 (2.8) 9 (1.0) 13 (1.3)
 5 1 (0.7) 5 (0.6) 6 (0.6)
Initial NIHSS score 17.0 [13.0;22.0] 12.0 [7.0;17.0] 12.5 [7.0;18.0] < 0.001
Modality of reperfusion therapy < 0.001
 IV tPA 43 (30.5) 501 (56.6) 544 (53)
 IA UK 5 (3.5) 16 (1.8) 21 (2)
 EVT 49 (34.8) 166 (18.8) 215 (21)
 Combined treatment 44 (31.2) 202 (22.8) 246 (24)
Myocardial infarction 16 (11.3) 45 (5.1) 61 (5.9) 0.006
Congestive heart failure 18 (12.8) 47 (5.3) 65 (6.3) 0.001
Peripheral artery obstructive disease 9 (6.4) 16 (1.8) 25 (2.4) 0.003
Previous stroke 39 (27.7) 168 (19.0) 207 (20.2) 0.023
Atrial fibrillation 84 (59.6) 439 (49.6) 523 (51.0) 0.035
Dementia 7 (5.0) 33 (3.7) 40 (3.9) 0.638
Depression 3 (2.1) 23 (2.6) 26 (2.5) 0.966
Pulmonary disease 7 (5.0) 33 (3.7) 40 (3.9) 0.638
Ulcer disease 12 (8.5) 21 (2.4) 33 (3.2) < 0.001
Mild liver disease 6 (4.3) 17 (1.9) 23 (2.2) 0.152
Moderate to severe renal disease 16 (11.3) 40 (4.5) 56 (5.5) 0.002
Connective tissue disease 0 (0.0) 6 (0.7) 6 (0.6) 0.7
Diabetes 93 (66.0) 342 (38.6) 435 (42.4) < 0.001
Anemia 61 (43.3) 209 (23.6) 270 (26.3) < 0.001
AIDS 0 (0.0) 1 (0.1) 1 (0.1) 1
Cancer 5 (3.5) 19 (2.1) 24 (2.3) 0.471
Leukemia 0 (0) 0 (0) 0 (0) NA
Lymphoma 3 (2.1) 1 (0.1) 4 (0.4) 0.005
Metastatic cancer 10 (7.1) 4 (0.5) 14 (1.4) < 0.001
Number of comorbidity 2.0 [2.0; 3.0] 1.0 [1.0; 2.0] 2.0 [1.0; 3.0] < 0.001
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In the prospective cohort, the predictive ability of the reperfusion comorbidity index considering initial stroke 
severity showed an area under the curve AUC of 0.821 (95% CI, 0.759–0.884). In the Hosmer and Lemeshow 
test, the p value was 0.098, indicating that the model was suitable (Supplemental Fig. 1B).
Discussion
In this study, we found that the patients who received reperfusion therapy frequently had comorbidities. Over 
80% of them had one or more comorbidities. Mortality within 6 months was significantly associated with the 
number of comorbidities. In a previous study, the comorbidity burden was a strong prognostic factor for both 
short- and long-term mortalities in patients with  stroke4. Comorbidities are closely related with each other 
and worsen the prognosis beyond that expected through the independent effects of each comorbid  condition4. 
Comorbidities may also influence the clinical outcomes of stroke in terms of the diagnostic process, treatment 
effects, complication rates, and  rehabilitation4,7.
We found that myocardial infarction, congestive heart failure, ulcer disease, diabetes mellitus, anemia, and 
metastatic cancer were independent predictors of mortality within 6 months. These comorbidities are known to 
be associated with an increased risk of mortality. Acute myocardial infarction complicating stroke accounts for 
20% of in-hospital mortality cases. In-hospital mortality is three-fold higher in patients with stroke and acute 
myocardial infarction than in those without the  latter8,9. Patients with stroke and congestive heart failure showed 
higher risks of mortality at 30 days (24.5%) and at 1 year (44.3%)10,11. Peptic ulcer disease was an independent 
risk factor for ischemic stroke and  mortality12. Almost 12% of patients with peptic ulcer disease died within 
1 year, and the main causes of mortality were cardiovascular disease and  malignancy13. Admission blood glucose 
level and history of diabetes mellitus are strong predictors of poor  outcomes14–16. Anemia on admission was also 
Figure 1.  Frequency (A) and association of the number of comorbidities with 6-month mortality (B).
Figure 2.  Nomogram (A) predicting mortality within 6 months and smartphone application (B). NIHSS, 
National Institutes of Health Stroke Scale score.
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associated with an increased risk of mortality in ischemic  stroke17. Cancer is unquestionably associated with the 
risk of  mortality14,18. The presence of metastasis is particularly associated with the short-term risk of mortality. 
Approximately two-thirds of patients with stroke and metastatic cancer died within 6 months after  stroke19.
There were slight differences of comorbidities between prediction of 6-month mortality and that of functional 
outcomes as 3 months. While metastatic cancer was a strong prognostic indicator for 6-month mortality, it was 
not associated with poor functional outcomes at 3 months. In contrast, dementia was associated with poor 
functional outcomes at 3 months, while it was not associated with 6-month mortality.
Herein, we included comorbidities based on the CCI. The CCI was developed as a prognostic indicator in 
patients with a variety of conditions admitted to a general medical  service6. It has been also proven to be a valid 
parameter for predicting mortality within 1 year and functional outcomes in patients with  stroke3,4. Patients with 
Table 2.  Univariable and multivariable analyses for the mortality within 6 months without considering initial 
stroke severity. OR, odds ratio.
Univariable Multivariable
OR (95% CI) p value OR (95% CI) p value
Age 1.042 (1.023–1.060) < 0.0001 1.036 (1.017–1.057) 0.0003
Sex (women) 1.179 (0.825–1.685) 0.3649
Myocardial infarction 2.389 (1.311–4.357) 0.0045 1.948 (1.010–3.755) 0.0465
Congestive heart failure 2.609 (1.468–4.639) 0.0011 1.939 (1.029–3.654) 0.0405
Peripheral artery obstructive disease 3.703 (1.604–8.552) 0.0022
Previous stroke 1.632 (1.088–2.448) 0.0179
Atrial fibrillation 1.497 (1.043–2.148) 0.0286
Dementia 1.349 (0.585–3.111) 0.4824
Depression 0.815 (0.241–2.750) 0.7414
Pulmonary disease 1.349 (0.585–3.111) 0.4824
Ulcerative disease 3.827 (1.839–7.966) 0.0003 2.770 (1.211–6.333) 0.0158
Liver disease 2.269 (0.879–5.857) 0.0903
Renal disease 2.704 (1.470–4.974) 0.0014
Connective tissue disease 0.479 (0.021–10.735) 0.6427
Diabetes 3.076 (2.117–4.470) < .0001 2.774 (1.877–4.099) < .0001
Anemia 2.466 (1.708–3.562) < .0001 1.745 (1.171–2.601) 0.0062
Cancer 1.659 (0.857–3.211) 0.1332
Metastatic cancer 14.874 (5.555–39.825) < .0001 16.656 (4.558–60.872) < .0001
Figure 3.  Internal validation (A) and external validation (B). The predictive ability of the reperfusion 
comorbidity index for 6-month mortality showed an area under the curve (AUC) of 0.747 (95% CI, 
0.704–0.790) in retrospective cohort (A). In the prospective cohort, the predictive ability of the reperfusion 
comorbidity index was AUC of 0.784 (95% CI, 0.709–0.859) (B).
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severe comorbidities were more likely to die during  hospitalization20. We slightly modified the CCI by removing 
or replacing some comorbidities considering that our study population consisted of patients with acute stroke. We 
also examined mortality within 6 months because we wanted to investigate the role of the comorbidity index as 
a parameter for selecting patients for reperfusion therapy. The 6-month survival was suggested in the guidelines 
as a criterion for alteplase treatment in patients with stroke and systemic malignancy. This study showed that our 
comorbidity index model may be useful for predicting mortality within 6 months in patients with acute stroke 
who are potential candidates for reperfusion therapy.
We developed an additional model that includes NIHSS score to comorbidities because NIHSS is routinely 
determined and a strong prognostic factor in acute stroke. For the model, 6 or 4 (when including NIHSS score) 
out of the 19 comorbidities were included on the basis of the odds ratios in the multivariate logistic regression 
analysis. A simple prognostic tool should be used for screening candidates of reperfusion therapy in busy emer-
gency rooms. Obtaining information on many individual comorbidities, such as those included in the CCI, is 
impractical in emergent conditions in relation to reperfusion therapy. The predictability of 6-month mortality of 
this models was similar to that of the original CCI model. Consideration of just 6 or 4 comorbidities instead of 
full comorbidities in the original CCI may be enough to predict mortality within 6 months in patients receiving 
reperfusion therapy. We also developed a nomogram and a smartphone application, which can be used easily 
and rapidly in busy emergency  rooms21.
Many index scores for reperfusion therapy to predict stroke outcomes have already been proposed. For exam-
ples, those include the Pittsburgh Response to Endovascular Therapy (PRE)  score22, the Stroke Prognostication 
Using Age and National Institutes of Health Stroke Scale (SPAN)  index23, the Totaled Health Risks in Vascular 
Events (THRIVE)  score24, the Houston Intra-Arterial Therapy (HIAT)  score25, and the HIAT2  score26. We sum-
marize a table of each scoring system and compared to our reperfusion comorbidity index (Supplemental table 6). 
The AUC value of our reperfusion comorbidity index was compatible with those of other scoring systems. Our 
comorbidity index is different from others in that it can be calculated before reperfusion therapy without further 
imaging analysis such as the Alberta stroke program early CT score (ASPECTS).
There are some limitations in this study. First, the study population was obtained from a nationwide registry, 
but in a single country with a single ethnicity. Comorbidities may be different among countries and ethnicities. 
Therefore, our model should be validated in other cohorts. Second, although a relatively large number of patients 
were included in this study, some comorbidities were not included in the final predictive model because of their 
very low prevalence. However, they may influence the outcomes. Although almost all necessary information on 
comorbidities were obtainable by thorough medical review, particularly in the prospective cohort. There still 
might be some comorbidities that were unobtainable due to various reasons. Third, we did not include some 
factors associated with the outcomes of the patients receiving reperfusion therapy for the predictive model (e.g. 
achievement of recanalization, infarction volume, and complication after reperfusion therapy, such as intracer-
ebral hemorrhage). We wanted to develop a model predicting 6-month mortality, which can be available before 
reperfusion therapy. Finally, our comorbidity index provides probability of mortality within 6 months to guide 
Figure 4.  Receiver-operating characteristic curve (ROC) comparison death within 6 months mortality 
according to two models (A) and achievement of recanalization (B). ROC comparison for death within 
6 months showed that the area under the curve (AUC) did `not differ between reperfusion comorbidity index 
(age + 6 comorbidities [myocardial infarction, congestive heart failure, ulcer disease, diabetes mellitus, anemia, 
and metastatic cancer]) and the original Charlson comorbidity index model (age + 16 comorbidities) (p = 0.112) 
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and help for decision making of reperfusion therapy. However, quality of life is also very important. The decision 
regarding reperfusion therapy should be individualized and further research is required.
In conclusion, we developed and validated our simple reperfusion comorbidity index to determine the prob-
ability of mortality within 6 months using a large actual-clinical setting multicenter cohort in stroke patients 
receiving reperfusion therapy. This model may be helpful for prediction of 6-month mortality regarding reperfu-
sion therapy in patients with acute ischemic stroke.
Methods
Patients. We analyzed data from the SElection CRiteria in Endovascular thrombectomy and Thrombolytic 
therapy (SECRET) registry. This nationwide registry included consecutive patients with hyperacute ischemic 
stroke who received intravenous thrombolysis or endovascular thrombectomy. The SECRET registry aimed at 
exploring the patient selection criteria for reperfusion therapy, especially in relation to clots, core, collaterals, and 
comorbidities. It included a retrospective cohort and a prospective cohort. The retrospective cohort included 
1026 patients from 15 hospitals who received treatment between January 2012 and December 2015. The pro-
spective cohort included 333 patients from 13 hospitals who received treatment between November 2016 and 
December 2017.
The SECRET registry collected the following data: (1) demographic and clinical data, (2) information on 
reperfusion therapy, (3) comorbidities, and (4) imaging data. We determined the modified Rankin scale score 
at 90 days, mortality within 6 months, and the cause of death. Recanalization was assessed using the modified 
treatment in cerebral infarction score (mTICI). Successful recanalization was defined as mTICI 2b or 3. Sympto-
matic intracerebral hemorrhage was defined in accordance with the European Cooperative Acute Stroke Study 
3  criteria2.
Comorbidities. We determined the presence of comorbidities based on the CCI, which is widely used to 
predict 1-year  mortality3,27. In this study, we modified the CCI, considering patients with stroke as the study 
population. We omitted paralysis from the original CCI because it is a common symptom or sign of stroke; 
conversely, we added  anemia17, atrial  fibrillation28, and  depression29 as comorbidities, as they are common and 
are known to be associated with patient outcomes. Further, we merged diabetes mellitus with and without end-
organ damage as diabetes mellitus. Finally, 19 comorbidities were included: myocardial infarction, congestive 
heart failure, peripheral vascular disease, previous stroke, atrial fibrillation, dementia, depression, chronic pul-
monary disease, ulcer disease, mild liver disease, moderate or severe renal disease, connective tissue disease 
or rheumatic disease, diabetes mellitus, anemia, acquired immune deficiency syndrome, non-metastatic solid 
tumor, leukemia, lymphoma, and metastatic cancer.
We collected full information on the 19 comorbidities after completion of the reperfusion therapy via his-
tory taking and the thorough review of medical records at each study hospital. Neurologists or trained research 
assistants (nurses) determined the presence of comorbidities according to the definition of a comorbidity (Sup-
plemental material). The number of comorbidities was categorized as 0, 1, 2, or ≥  34.
Statistical analysis. Data were expressed as means ± SDs, medians and interquartile ranges (IQRs), or 
frequencies (percentages), as appropriate. Variables were tested for normality using the Kolmogorov–Smirnov 
test. Differences between the groups were compared using an independent sample t-test or the Mann–Whitney 
U-test for continuous variables and the chi-square test for categorical variables.
We developed a statistical model to predict 6-month mortality using univariate and multivariate logistic 
regression analyses with backward (Wald) selection of predictors in the retrospective cohort (the reperfusion 
comorbidity index). A multivariate analysis was performed using all variables with p values of < 0.05 in the 
univariate analysis. Comorbidities including leukemia, lymphoma, AIDS with a low prevalence (n < 5) were 
excluded in the multivariate analysis model. Therefore, 16 comorbidities were analyzed. We also developed 
another statistical model that added the National Institutes of Health Stroke Scale (NIHSS) score to comorbidi-
ties. The models were validated using data from a prospective cohort.
We determined the area under the receiver-operating characteristic curve (ROC) to predict 6-month mortal-
ity. The Hosmer and Lemeshow goodness-of-fit test was used to assess the acceptability of the predictive models. 
This test also determined how well the nomogram was calibrated. Close approximation between the observed 
and predicted probabilities demonstrated good calibration and confirmed the exportability of the model. We 
compared the predictability of the reperfusion comorbidity index with that of the original CCI. We also compared 
the AUC between the patients with recanalization and those without successful recanalization.
The nomogram for predicting 6-month mortality was constructed on the basis of the multivariate models with 
data from the retrospective cohort. Validation was performed using the prospective cohort. We also developed 
iPhone and android smartphone applications. The applications calculated the probability of 6-month mortality 
upon selection of comorbidities.
All p values were two-sided. p values of < 0.05 were considered significant. Statistical analyses were performed 
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) and R package version 3.1.2 (R Foundation for Statisti-
cal Computing, Vienna, Austria; http://www.R-proje ct.org).
Standard protocol approval, registration, and patient consent. The study is registered to Clinicaltrials.gov 
(NCT02964052). The study and registry were approved by the institutional review board (Yonsei University 
College of Medicine, 4-2015-1196). All methods were performed in accordance with the relevant guidelines and 
regulations. For the prospectively enrolled patients, written informed consent was obtained from the patients 
themselves or their next of kin.
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Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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